Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains.

Bidwell LC, Mueller R, YorkWilliams SL, Hagerty S, Bryan AD, Hutchison KE.

Cannabis Cannabinoid Res. 2018 Mar 1;3(1):35-44. doi: 10.1089/can.2017.0038. eCollection 2018.

2.

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.

Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, Yücel M.

Cannabis Cannabinoid Res. 2018 Mar 1;3(1):21-34. doi: 10.1089/can.2017.0043. eCollection 2018.

3.

The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment.

Gruber SA, Sagar KA, Dahlgren MK, Gonenc A, Smith RT, Lambros AM, Cabrera KB, Lukas SE.

Front Pharmacol. 2018 Jan 17;8:983. doi: 10.3389/fphar.2017.00983. eCollection 2017.

4.

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B.

PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018.

5.

A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ⁸-Tetrahydrocannabinol.

Sultan SR, Millar SA, O'Sullivan SE, England TJ.

Pharmaceuticals (Basel). 2018 Jan 31;11(1). pii: E13. doi: 10.3390/ph11010013. Review.

6.

Commentary on "The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis".

McGuire P, Englund A, Bhattacharyya S.

Schizophr Bull. 2018 Jan 13;44(1):18-19. doi: 10.1093/schbul/sbx124. No abstract available.

PMID:
29346673
7.

Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

Udow SJ, Freitas ME, Fox SH, Lang AE.

CMAJ. 2018 Jan 15;190(2):E50-E52. doi: 10.1503/cmaj.170361. No abstract available.

PMID:
29335263
8.

Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors.

Bhattacharyya S, Egerton A, Kim E, Rosso L, Riano Barros D, Hammers A, Brammer M, Turkheimer FE, Howes OD, McGuire P.

Sci Rep. 2017 Nov 3;7(1):15025. doi: 10.1038/s41598-017-14203-4.

9.

Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment.

Murphy M, Mills S, Winstone J, Leishman E, Wager-Miller J, Bradshaw H, Mackie K.

Cannabis Cannabinoid Res. 2017 Sep 1;2(1):235-246. doi: 10.1089/can.2017.0034. eCollection 2017.

10.

The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Hahn B.

Schizophr Bull. 2018 Jan 13;44(1):46-53. doi: 10.1093/schbul/sbx105.

PMID:
29083450
11.

A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders.

Lim K, See YM, Lee J.

Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):301-312. doi: 10.9758/cpn.2017.15.4.301. Review.

12.

Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion.

Freeman TP, Pope RA, Wall MB, Bisby JA, Luijten M, Hindocha C, Mokrysz C, Lawn W, Moss A, Bloomfield MAP, Morgan CJA, Nutt DJ, Curran HV.

Int J Neuropsychopharmacol. 2018 Jan 1;21(1):21-32. doi: 10.1093/ijnp/pyx082.

13.

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M.

Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6.

PMID:
28875990
14.

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.

Iffland K, Grotenhermen F.

Cannabis Cannabinoid Res. 2017 Jun 1;2(1):139-154. doi: 10.1089/can.2016.0034. eCollection 2017. Review.

15.

Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults.

Arndt DL, de Wit H.

Cannabis Cannabinoid Res. 2017 Jun 1;2(1):105-113. doi: 10.1089/can.2017.0014. eCollection 2017.

16.

Identification of Terpenoid Chemotypes Among High (-)-trans9- Tetrahydrocannabinol-Producing Cannabis sativa L. Cultivars.

Fischedick JT.

Cannabis Cannabinoid Res. 2017 Mar 1;2(1):34-47. doi: 10.1089/can.2016.0040. eCollection 2017.

17.

Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004.

Grotenhermen F, Russo E, Zuardi AW.

Cannabis Cannabinoid Res. 2017 Jan 1;2(1):1-4. doi: 10.1089/can.2016.0036. eCollection 2017.

18.

Evaluation of Oxidant/Antioxidant Status and Cytokine Levels in Patients with Cannabis Use Disorder.

Bayazit H, Selek S, Karababa IF, Cicek E, Aksoy N.

Clin Psychopharmacol Neurosci. 2017 Aug 31;15(3):237-242. doi: 10.9758/cpn.2017.15.3.237.

19.

Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels.

Scott CE, Kendall DA.

Methods Enzymol. 2017;593:317-342. doi: 10.1016/bs.mie.2017.05.002. Epub 2017 Jul 5.

20.

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.

Morales P, Reggio PH, Jagerovic N.

Front Pharmacol. 2017 Jun 28;8:422. doi: 10.3389/fphar.2017.00422. eCollection 2017. Review.

Supplemental Content

Support Center